Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down

Madrigal Pharmaceuticals (MDGL) is down 4.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is that the move was driven by profit-taking rather than a clear negative company-specific development. Recent updates pointed to continued pipeline progress and supportive Wall Street coverage, so the selloff could be because investors used strength in the shares to lock in gains after a strong run in late June.

Details:

MDGL had climbed notably in the sessions leading into the drop, including gains on June 29 and June 30, which can set up a pullback in a volatile biotech name.

A late-June analyst note maintained a positive rating and a $600 price target, so there was no obvious bearish rating change tied to the decline.

On July 1, a partnership update tied to Madrigal’s siRNA efforts in MASH highlighted a milestone that advanced IND-enabling work, which does not point to a negative operational surprise.

The company’s most recent quarterly update showed strong Rezdiffra revenue growth and more than 42,000 patients on therapy as of March 31, 2026, suggesting the fundamental backdrop remained intact.

Sources:

Madrigal Pharmaceuticals, SEC, Google Finance, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDGL Insider Trading Activity

$MDGL insiders have traded $MDGL stock on the open market 97 times in the past 6 months. Of those trades, 0 have been purchases and 97 have been sales.

Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:

PAUL A FRIEDMAN has made 0 purchases and 29 sales selling 24,800 shares for an estimated $12,963,304.
REBECCA TAUB has made 0 purchases and 33 sales selling 22,026 shares for an estimated $11,378,413.
RICHARD S LEVY has made 0 purchases and 12 sales selling 5,682 shares for an estimated $2,928,716.
WILLIAM JOHN SIBOLD (President and CEO) has made 0 purchases and 2 sales selling 3,240 shares for an estimated $1,494,862.
MARDI DIER (EVP and CFO) has made 0 purchases and 13 sales selling 3,165 shares for an estimated $1,359,381.
DAVID SOERGEL (Chief Medical Officer) has made 0 purchases and 2 sales selling 1,886 shares for an estimated $951,980.
CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 3 sales selling 1,329 shares for an estimated $630,321.
SHANNON T KELLEY (General Counsel) has made 0 purchases and 3 sales selling 1,052 shares for an estimated $499,671.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MDGL Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MDGL Hedge Fund Activity

We have seen 176 institutional investors add shares of $MDGL stock to their portfolio, and 166 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 417,709 shares (+1156.0%) to their portfolio in Q1 2026, for an estimated $218,658,130
PAULSON & CO. INC. removed 315,334 shares (-18.5%) from their portfolio in Q1 2026, for an estimated $165,067,888
WELLINGTON MANAGEMENT GROUP LLP added 233,556 shares (+50.6%) to their portfolio in Q1 2026, for an estimated $122,259,559
BANK OF AMERICA CORP /DE/ removed 226,498 shares (-54.4%) from their portfolio in Q1 2026, for an estimated $118,564,908
ALKEON CAPITAL MANAGEMENT LLC removed 160,000 shares (-66.7%) from their portfolio in Q1 2026, for an estimated $83,755,200
TORONTO DOMINION BANK added 130,460 shares (+inf%) to their portfolio in Q1 2026, for an estimated $68,291,896
ASSENAGON ASSET MANAGEMENT S.A. added 108,181 shares (+674.7%) to their portfolio in Q2 2026, for an estimated $58,087,787

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDGL Analyst Ratings

Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citizens issued a "Market Outperform" rating on 01/20/2026

To track analyst ratings and price targets for $MDGL, check out Quiver Quantitative's $MDGL forecast page.

$MDGL Price Targets

Multiple analysts have issued price targets for $MDGL recently. We have seen 7 analysts offer price targets for $MDGL in the last 6 months, with a median target of $649.0.

Here are some recent targets:

Alexandria Hammond from B of A Securities set a target price of $542.0 on 06/11/2026
Srikripa Devarakonda from Truist Securities set a target price of $709.0 on 05/13/2026
Liisa Bayko from Evercore ISI Group set a target price of $649.0 on 05/07/2026
Edward Nash from Canaccord Genuity set a target price of $578.0 on 05/07/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $620.0 on 05/06/2026
Eliana Merle from Barclays set a target price of $964.0 on 01/28/2026
Jonathan Wolleben from Citizens set a target price of $745.0 on 01/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.